Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • News

Curis To Present Updated Data From TakeAim Leukemia Study At The ASCO And EHA Conferences

By Benzinga Newsdesk
May 14, 4:02 PM
Data update expands AML dataset from 5 to 30 patientsLEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally

CRIS

Read More
1 minute read
  • Biotech
  • General
  • News

Beam Therapeutics Presents Data Highlighting Robust Manufacturing Process For BEAM-101 At EHA 2024 Hybrid Congress June 13-16, 2024

By Benzinga Newsdesk
May 14, 4:00 PM
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated

BEAM

Read More
1 minute read
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Initiation
  • News
  • Top Stories
  • Trading Ideas

DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst

By Vandana Singh
May 14, 2:37 PM
Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non-surgical RRP treatment.

INO

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Trading Ideas

Pliant Therapeutics’ Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients

By Vandana Singh
May 14, 10:39 AM
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis reversal.

PLRX

Read More
1 minute read
  • Biotech
  • General
  • News

Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress

By Benzinga Newsdesk
May 14, 10:12 AM
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse

AFMD

Read More
1 minute read
  • Biotech
  • General
  • News

Editas Medicine To Present Clinical Data From The RUBY And EdiTHAL Trials Of Reni-cel At The EHA 2024 Congress In June

By Benzinga Newsdesk
May 14, 10:10 AM
Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and

EDIT

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

FDA Declines To Approve Expanded Use of Dynavax’s Hepatitis B Vaccine In Hemodialysis Patients

By Vandana Singh
May 14, 10:10 AM
Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Response Letter.

DVAX

Read More
1 minute read
  • Biotech
  • General
  • News

Nurix Therapeutics Upcoming Oral Presentation Of Data From Ongoing Clinical Trial Of NX-5948, A Selective BTK Degrader, At EHA2024 June 13 – 16, 2024, In Madrid, Spain

By Benzinga Newsdesk
May 14, 10:04 AM
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance

NRIX

Read More
1 minute read
  • Biotech
  • General
  • News

Kymera Therapeutics Present’s Clinical Data From The Ongoing Phase 1 Trial Of STAT3 Degrader KT-333 At EHA Annual Meeting June 13-16, 2024, In Madrid, Spain

By Benzinga Newsdesk
May 14, 10:03 AM
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual

KYMR

Read More
1 minute read
  • Biotech
  • General
  • News

Celularity’s Published In ‘Journal For ImmunoTherapy Of Cancer’ Reveals Placental Circulating T Cells For CAR-T Therapy

By Benzinga Newsdesk
May 14, 9:18 AM
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal

CELU

Posts pagination

Previous 1 … 31 32 33 … 733 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service